No different than many of the OTC stocks I've seen. The biggest supporters become the harshest critics for varying reasons.
Few (if any) are happy with the PPS drop over the last couple of months. There are always those who like to grab "cheapies". Voicing frustrations on this board or elsewhere is expected.
I jumped in this stock a little bit ago anticipating good news in the 2nd half of the year. Even if the O/S is fully diluted according to the various agreements, IMO the float is still low enough for this to move significantly with good news. There is always risk though. Everyone should have their own plan worked out.
I'm not sure what ILNS would be able to say right now. Seems like the TauC3 is still being studied. The data for Phase 1B of OX1/SHP622 is still being evaluated. Maza might know the preliminary results of Shire's clinical tests, but he's not putting that info out before Shire is ready.
Unless there is a significant milestone payment later this year, IMO they will have to raise more money for 2016.
Unless shareholders have the majority of the vote, they aren't going to be able to replace Maza. Most OTC CEOs should know that. That is why they keep a poison pill in their back pocket and probably why the ILNS A/S is still at 2B.
For me, it's a waiting game.
News 
Market Data 
Discover 
